RETROVIRAL NUCLEIC MATERIAL AND NUCLEOTIDE FRAGMENTS, IN PARTICULAR ASSOCIATED WITH MULTIPLE SCLEROSIS AND/OR RHEUMATOID ARTHRITIS, FOR DIAGNOSTIC, PROPHYLACTIC AND THERAPEUTIC USES
Matériel nucléique, à l'état isolé ou purifié, et fragment nucléotidique, comprenant une séquence nucléotidique choisie dans le groupe qui consiste en (i) les séquences SEQ ID NO : 6, SEQ ID NO : 9, SEQ ID NO : 12, SEQ ID NO : 21, SEQ ID NO : 30 et SEQ ID NO : 31; (ii) les séquences complémenta...
Gespeichert in:
Hauptverfasser: | , , , , , , , |
---|---|
Format: | Patent |
Sprache: | eng ; fre |
Schlagworte: | |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Matériel nucléique, à l'état isolé ou purifié, et fragment nucléotidique, comprenant une séquence nucléotidique choisie dans le groupe qui consiste en (i) les séquences SEQ ID NO : 6, SEQ ID NO : 9, SEQ ID NO : 12, SEQ ID NO : 21, SEQ ID NO : 30 et SEQ ID NO : 31; (ii) les séquences complémentaires des séquences (i); et (iii) les séquences équivalentes aux séquences (i) ou (ii), en particulier les séquences présentant pour toute suite de 100 monomères contigus, au moins 50 %, et préférentiellement au moins 70 % d'homologie avec respectivement les séquences (i) ou (ii), et utilisations pour détecter un rétrovirus associé à la sclérose en plaques.
The following are claimed: (1) isolated or purified nucleic acid material comprising a nucleotide sequence selected from (i) the 310 bp, 635 bp, 1481 bp, 1329 bp, 1511 bp, 764 bp, 800 bp sequences given in the specification; (ii) sequences complementary to the sequences of (i); and (iii) sequences equivalent to the sequences of (i) and (ii), especially sequences having at least 50%, preferably at least 70%, homology with the sequences of (i) or (ii) for any stretch of 100 contiguous monomers; (2) isolated or purified nucleic acid material encoding a polypeptide having at least 50%, preferably at least 70%, homology with a peptide sequence selected from the 103, 77, 493, 162, 398 and 378 amino acid sequences given in the specification for any contiguous stretch of at least 30 amino acids; (3) retroviral nucleic acid material in which the pol gene comprises a nucleotide sequence identical or equivalent to the 310 bp sequence and its complements; (4) retroviral nucleic acid material in which the 5' end of the pol gene starts at nucleotide 1419 of the 1511bp sequence; (5) retroviral nucleic acid material in which the pol gene encodes a polypeptide having at least 50%, preferably at least 70%, homology with the 103 amino acid sequence for any contiguous stretch of at least 30 amino acids; (6) retroviral nucleic acid material in which the 3' end of the gag gene ends at nucleotide 1418 of 1511bp sequence; (7) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence identical or equivalent to a sequence selected from 1481bp sequence and its complement; (8) retroviral nucleic acid material in which the env gene comprises a nucleotide sequence that starts at nucleotide 1 of the 1481 bp sequence and ends at nucleotide 233 of the 635 bp sequence; (9) retroviral nucleic acid material in which the e |
---|